Managing the risks of the Covid-19 pandemic remains a challenge. While EU vaccination rates have reached three quarters of the population, new SARS-CoV-2 variants keep emerging in the EU. Although these variants appear to be generally less severe, they still pose challenges to health systems. The implementation of a globally effective vaccine strategy remains key to enhancing Europe's resilience. If measures are successful, it is expected that SARS-CoV-19 – while still present – will enter a stage of seasonality, characterised by higher case numbers in the winter months, similarly to the flu. To achieve this, rethinking present surveillance and monitoring schemes, ensuring the distribution of vaccines worldwide and implementing an action plan against disinformation and misinformation could be crucial.

EPRS STOA podcast - Responding better to future pandemics

Vi vet att vacciner är effektiva verktyg. Tack vare dem har många tidigare dödliga sjukdomar kunnat utrotas. Under coronakrisen satsar EU extra på forskning om vacciner. Så här till exempel.

Det här gör EU för forskare som försöker hitta vaccin

<p>Vaccines are a key part of a long-term strategy to bring SARS-CoV-2 under control. It is essential to roll out vaccination rapidly to protect as many people as possible and to lower the opportunities for the virus to evolve further. Any vaccine must be authorised by the European Medicines Agency (EMA).</p>

<p>The European Commission has secured up to 4.4 billion doses of COVID-19 vaccines so far - and negotiations are underway for additional doses. However, countries are facing different challenges around the disinformation or vaccine acceptance. The European Parliament is trying to keep an eye on the purchase and safety of these vaccines. During June plenary the EP adopted a resolution calling for COVID-19 vaccine patent waiver. Parliament proposed negotiations start for a temporary waiver of the WTO TRIPS Agreement on patents to improve global access to affordable COVID-19-related medical products and to address global production constraints and supply shortages. The EP approved also the Digital Green Certificate to facilitate the safe free movement of citizens within the EU during the pandemic.</p>

EU Vaccine Strategy

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee - Exchange of views with external experts on COVID-19 vaccines

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation

Öppnande av sammanträdet

Tillkännagivande av omröstningsresultat

Amerikanska restriktiva åtgärder och rättsstatlighet (debatt)

Första omröstningsomgången

Amerikanska restriktiva åtgärder och rättsstatlighet

Regeringens tillslag mot protester och medborgare i Kuba

Fallet med människorättsförsvararen Ahmed Mansoor i Förenade Arabemiraten

Situationen i flyktinglägret Kakuma i Kenya

Återupptagande av sammanträdet

Tillkännagivande av omröstningsresultat: se protokollet

Utskottens och delegationernas sammansättning

Andra omröstningsomgången

Transparens i EU i samband med utveckling, inköp och distribution av covid-19-vaccin (debatt)

Justering av protokoll från denna sammanträdesperiod och översändande av antagna texter: se protokollet

Datum för nästa sammanträdesperiod: se protokollet

Avslutande av sammanträdet

Avbrytande av sessionen

Plenary session

Hanteringen av de globala utmaningarna till följd av covid-19: effekterna av undantaget från WTO:s Trips-avtal för vacciner, behandling, utrustning och produktionskapacitet i utvecklingsländerna när det gäller covid-19 (debatt)

Den tjeckiska premiärministerns intressekonflikt (debatt)

Första omröstningsomgången (fortsättning)

Europeiska unionens byrå för grundläggande rättigheter: interimsbetänkande (debatt)

Nya vägar för laglig arbetskraftsmigration (debatt)

EU:s digitala framtid: digital inre marknad och användningen av AI för europeiska konsumenter (debatt)

Företagens ansvar för miljöskador (debatt)

Företagens ansvar för miljöskador (debatt) (fortsättning på debatten)

Betydelsen av civilrättslig rättvisa i samband med den ekonomiska återhämtningen efter covid-19 (debatt)

Miljö: Århusförordningen (debatt)

Europeiska kompetenscentrumet för cybersäkerhet (debatt)

Fiscalisprogrammet för samarbete på beskattningsområdet 2021–2027 (debatt)

Föredragningslista för nästa sammanträde: se protokollet

Statements by Pascal CANFIN and by Cristian-Silviu BUŞOI, ITRE Chair on "COVID 19 vaccine production and delivery"

Webinar on Vaccines – A united response to beat the Covid-19 virus

Covid-19-åtgärdernas effekter på demokratin, rättsstatsprincipen och de grundläggande rättigheterna (debatt)

Covid-19-åtgärdernas effekter på demokratin, rättsstatsprincipen och de grundläggande rättigheterna (fortsättning på debatten)

Program för unionens åtgärder på hälsoområdet för perioden 2021–2027 (programmet EU för hälsa) (debatt)

Transparens i samband med inköp av och tillgång till vaccin mot covid-19 (debatt)

Parlamentets sammansättning: se protokollet

Investeringsplanen för ett hållbart Europa – finansieringen av den gröna given (debatt)

Val av Europaparlamentets första vice talman (som ska ersätta Mairead McGuinness) (omröstning): se protokollet

Utskottens och delegationernas sammansättning: se protokollet

Rättelser (artikel 241 i arbetsordningen) (uppföljning): se protokollet

Plenary Session

ENVI-ITRE Joint Hearing on "How to secure access to COVID-19 vaccines for EU citizens: clinical trials, production and distribution challenges"

ITRE

ENVI

Ändring av föredragningslistan: se protokollet

Tillkännagivande av resultaten av omröstningarna

Undantagslagstiftning i Ungern och dess effekter för rättsstatsprincipen och de grundläggande rättigheterna (debatt)

Första omröstningen

Undantagslagstiftning i Ungern och dess effekter för rättsstatsprincipen och de grundläggande rättigheterna (fortsättning på debatten)

70-årsdagen av Schumandeklarationen (debatt)

Användning av kontaktspårningsappar för att bekämpa coronaviruset (debatt)

Andra omröstningen

Vacciner och behandlingar mot covid-19 (debatt)

Rättelse (artikel 241 i arbetsordningen) (vidtagna åtgärder): se protokollet

Tredje omröstning

Vaccine hesitancy and drop in vaccination rates in Europe (debate)

Tuberculosis Vaccine Initiative (debate)

Problem of limited access of developing countries to some vaccines (debate)

EP Plenary session  - EU transparency in the development, purchase and distribution of COVID-19 vaccines

EP Plenary session - Meeting the Global Covid 19 challenge: effects of waiver of the WTO TRIPS agreement on Covid-19 vaccines, treatment, equipment and manufacturing capacity in developing countries

Stockshot picture showing what could be a COVID-19 Green Certificate for traveling

ENVI Committee - Exchange of views with  Emer Cooke,EMA Executive Director, on the update of evaluation and authorisation of COVID-19 vaccines

ENVI Committee - COVID-19 variants and the vaccines' efficacy

ENVI- ITRE joint Committee -  Hearing on  ' How to increase the capacity of COVID 19 vaccine production and improve delivery 'Press point

ENVI- ITRE joint Committee -  Hearing on  ' How to increase the capacity of COVID 19 vaccine production and improve delivery '- Session 2

ENVI- ITRE joint Committee -  Hearing on  ' How to increase the capacity of COVID 19 vaccine production and improve delivery 'Session 1

ENVI- ITRE joint Committee -  Hearing on  ' How to increase the capacity of COVID 19 vaccine production and improve delivery '- Welcome and opening remarks

DEVE Committee - Access to COVID-19 vaccines for developing countries - exchange of views with Jutta URPILAINEN, Commissioner for International Partnerships

David SASSOLI, EP President in video meeting with Dr Franklin BERKLEY, CEO of The Vaccine Alliance

BUDG Committee - Financing from the EU budget in the context of the EU vaccines strategy

Statement by Pascal CANFIN, Chair of ENVI Committee on Vaccine deliveries and contracts transparency

Coronavirus - Vaccinations of healthcare professionals

ENVI - Committee on Environment, Public Health and Food Safety - Exchange of views with the Commission on the issue of vaccines in the EU

ENVI -  Committee on the Environment, Public Health and Food Safety - State of play with the assessment and authorization of vaccines against COVID-19 - Exchange of views with Emer COOKE, Executive Director of the European Medicines Agency (EMA)

Vaccination campaign

This infoclip shows how the European Parliament responded to COVID pandemic from March 2020 with distancing activities of the European Parliament held by David SASSOLI, EP President until the press conference to present the results of the work of the Committee on collecting the evidence and lessons learned from the COVID-19 pandemic as well as to give answers on the impact it had on citizens and their fundamental rights, the businesses, the health sector and international community in June 2023. This infoclip shows illustrations of EP buildings used in the fight against COVID-19, the Green corridor at the Belgium-Dutch border, digital COVID certificates, trilogue on the EU COVID-19 certificate, meetings of the Special COVI Committee, vaccines production and distribution, COVID-19 pandemic: lessons learned and recommendations for the future: extracts from the voteand from the press conference

European Parliament’s priorities and achievements (2019-2024): Response to COVID pandemic

Ahead of the 17-18 February European Union-African Union summit in Brussels, MEPs review the EU’s relations with Africa on Tuesday afternoon. The discussion focuses on the common challenges facing both continents, including the recovery from the COVID-19 pandemic, boosting vaccination and stimulating investments. Closing statement by Josep BORRELL, Vice-President of the Commission/High Representative of the Union for Foreign Affairs and Security Policy.

EU-Africa relations: closing statement by Josep BORRELL, Vice-President of the Commission/High Representative of the Union for Foreign Affairs and Security Policy

During the plenary session (13-16 September 2021) in the European Parliament in Strasbourg, MEPs participate in the debate on the EU transparency in the development, purchase and distribution of COVID-19 vaccines. Opening statements by Dolors MONTSERRAT (EPP, ES), Author and by Ylva JOHANSSON, European Commissioner for Home Affairs on behalf of Stella KYRIAKIDES, European Commissioner for Health and Food Safety. This transcription speech is the result of an automatic process. Check against delivery.

EU transparency in the development, purchase and distribution of COVID-19 vaccines - O.Q. to Commission: opening statements by Dolors MONTSERRAT (EPP, ES), Author and by Ylva JOHANSSON, European Commissioner for Home Affairs

During the plenary session (13-16 September 2021) in the European Parliament in Strasbourg, MEPs participate in the debate on the EU transparency in the development, purchase and distribution of COVID-19 vaccines.

EU transparency in the development, purchase and distribution of COVID-19 vaccines - O.Q. to Commission: MEPs debate

During the plenary session (13-16 September 2021) in the European Parliament in Strasbourg, MEPs participate in the debate on the EU transparency in the development, purchase and distribution of COVID-19 vaccines. Closing statement by Ylva JOHANSSON, European Commissioner for Home Affairs on behalf of Stella KYRIAKIDES, European Commissioner for Health and Food Safety.

EU transparency in the development, purchase and distribution of COVID-19 vaccines - O.Q. to Commission: closing statement by Ylva JOHANSSON, European Commissioner for Home Affairs

Announcement of the results of the voting session (09/06) during the plenary session (7-10 June 2021) in the European Parliament in Strasbourg. Final votes on the conflict of interest of the Czech Prime Minister and the agreement on Covid-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries and others. The results of the vote on the conflict of interest of the Czech Prime Minister are 690 voting - 505 in favour - 30 against - 155 abstentions. The results of the vote on WTO TRIPS (vaccine agreement) are 689 voting - 355 in favour - 263 against - and 71 abstentions.

Announcement of the results of the voting session (09/06): final votes on the conflict of interest of the Czech Prime Minister, and the agreement on Covid-19 vaccines and others

During the plenary session (7-10 June 2021) in the European Parliament in Strasbourg, MEPs debate on the conclusions of the special meeting of the European Council on 24 and 25 May 2021: extracts from the debates on EU Vaccines strategy. Statements by Charles MICHEL, President of the European Council, Ursula VON DER LEYEN, President of the EC, Manfred WEBER (EPP, DE), Iratxe GARCÍA PÉREZ (S&D, ES), Dacian CIOLOŞ (Renew, RO), Ska KELLER (Greens/EFA, DE), and Beata SZYDŁO (ECR, PL).

EU Vaccines strategy: extracts from the debate

Parlamentet debatterade om huruvida patent på covid-19-vaccin bör slopas och antog ett mer inkluderande Erasmus+-program. Klimatet stod också på dagordningen: Parlamentsledamöterna godkände Fonden för en rättvis omställning för att hjälpa regioner under den gröna omställningen, och uppmanade EU att göra mer för att skydda miljöaktivister. Parlamentsledamöterna diskuterade även upptrappningen av konflikten mellan Israel och Palestina.

Höjdpunkter från plenarsammanträdet: Vaccinpatent för covid-19, Erasmus+ och miljön

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate proposal to the WTO to waive intellectual property rights for COVID-19 vaccines, a move backed by the US administration. Extracts from the debate: statements by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs, Valdis DOMBROVSKIS, Executive Vice-President of the EC in charge of an Economy that works for People, Esther de LANGE (EPP, NL), Iratxe GARCÍA PÉREZ (S&D, ES), Dacian CIOLOŞ (Renew, RO), Tilly METZ (Greens/EFA, LU), Marc BOTENGA (The Left, BE), and Gilles LEBRETON (ID, FR).

Waiver of the Global Covid 19 vaccines patents: extracts from the debate

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 1/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 1/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Closing statements by Valdis DOMBROVSKIS, Executive Vice-President of the European Commission in charge of an Economy that works for People, and Commissioner for Trade and by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Closing statements by Council and Comission

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 3/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 3/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 2/3

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: MEPs debate part 2/3

During the plenary session of the European Parliament in Brussels (17-20 May 2021), MEPs debate on the meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Opening statements by Augusto SANTOS SILVA, Portuguese Minister of State for Foreign Affairs and by Valdis DOMBROVSKIS, Executive Vice-President of the European Commission in charge of an Economy that works for People, and Commissioner for Trade.

Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and manufacturing capacity in developing countries: Opening statements Council and Commission

Members of the Environment, Public Health and Food Safety (ENVI) Committee had an exchange of views on a new legislation for a faster authorisation procedure for COVID-19 vaccines that have already received EU authorisation, but which are being adapted to be effective against variants of the virus.

Quicker authorization procedure for adapted COVID-19 vaccines: exchange of views and statement by Cristian-Silviu BUŞOI (EPP, RO), Chair of the EP Committee on Industry, Research and Energy

The EU Digital COVID Certificate aimed to ensure the freedom of movement within the EU during the pandemic.The Certificate would constitute proof that a person has been either vaccinated against COVID-19, received a negative test result, or already recovered from the disease. This infoclip shows traveller presenting their Digital Certificate (fiction - posed scenes), people receiving the vaccine against COVID-19 and being tested.

Infoclip: EU Digital COVID Certificate (posed scenes)

During the plenary session (24-25 March 2021) in the European Parliament in Brussels, MEPs debate the export transparency and authorisation mechanism for COVID-19 vaccine after the European Commission has introduced the principles of reciprocity and proportionality as new criteria to be considered for authorising exports. Statements by Maros SEFCOVIC, Vice-President of the EC in charge of Interinstitutional relations and Foresight, Manfred WEBER (EPP, DE), Chair of the EPP Group, Iratxe GARCÍA PÉREZ (S&D, ES), Chair of the S&D Group, Katalin CSEH (Renew, HU), and Martin SCHIRDEWAN (The Left, DE), Co-chair of the Left Group.

Export transparency and authorisation mechanism of COVID19 vaccines: extracts

Emer COOKE, European Medicines Agency (EMA) Executive Director update MEPs from the Environment, Public Health and Food Security Committee on the state of play in the evaluation and market authorisation of vaccines against COVID-19 and the next steps. And Members of the Budgets Control Committee and the Commission’s Director-General for Health and Food Safety (SANTE), Sandra GALLINA, discuss the current state of the EU’s advance purchase agreement on vaccines against COVID-19.

Update of purchase, evaluation and authorization of COVID-19 vaccines: extracts from the exchanges of views with Sandra GALLINA, Director-General of DG SANTE (CONT) and with Emer COOKE, EMA Executive Director (ENVI)

Visar 761 bilder resultat för ""

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee - Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee - Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee - Exchange of views with external experts on COVID-19 vaccines

COVI Special Committee.- Exchange of views with external experts on COVID-19 vaccines

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation

DEVE/AFET Commitees - Access to vaccines in developing countries - Exchange of views with the European Commission, EEAS and representatives of international organisation